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In 1998, 3.6% (5,874/100,000) of all active M.
tuberculosis (TB) cases reported in the United
States were  residents of correctional facilities - a
TB case rate that is 50 times that of non-incar-
cerated individuals (1). This high proportion of
cases is due to a combination of factors, including
the high prevalence of TB infection in the incar-
cerated population, aggressive case finding
among a high-risk group that often has limited
access to other health care services, and the
ready transmission of TB in these congregate liv-
ing environments.
The factor that most increases the probability that
TB infection will progress to active disease is
immune deficiency, such as that caused by co-
infection with HIV. At year-end 1996, 21,799
(2.3%) of all state and federal prison inmates
were known to be infected with HIV (2). The over-
all rate of confirmed cases of AIDS among the
nation’s prison population (0.54%) was six times
the rate in the U.S. population (0.09%) Thus, one
reason residents of correctional facilities have a
high risk for TB disease is that a disproportion-
ately high number of them have HIV infection.
The Advisory Council for the Elimination of
Tuberculosis (ACET) has recently published a
document that advocates developing, implement-
ing, and focusing strategies for TB control among
segments of the population identified as having a
high TB risk. (3). One strategy that will be
reviewed in this article is maintaining aggressive
policies for screening the inmates for TB infection,
and initiating and completing therapy regimens
for latent M. tuberculosis infection (MTB infection)
when indicated. Updated guidelines highlighting
new regimens and clinical practices for persons
with MTB infection are scheduled for release this
spring in MMWR and the American Journal of
Respiratory Critical Care in Medicine (4)1.  This
article discusses current guidelines for treating
and preventing TB in corrections2. 
Initial Tuberculosis Screening
The following procedures should be used for the
initial screening of inmates, depending on their
length of stay in the facility and the type of facility
(5, 6). According to the Essential Standard P-32
of the National Commission on Correctional
Health Care Prison Standards, symptom screen-
ing should be done during intake for all new
inmates, regardless of anticipated length of sen-
tence ("Standards" available at www.ncchc.org).
Any inmate with symptoms suggestive of TB
(chronic productive cough, fever, and/or weight
loss) should be immediately placed in a negative
pressure respiratory isolation room (TB isolation
room) and promptly evaluated for TB disease. In
addition, tuberculin skin test (TST) screening of
all inmates without a documented positive
Mantoux skin test result should be mandatory,
although this may not be feasible for short-term
inmates. Persons with a positive skin test reaction
should receive a chest radiograph, a thorough
medical evaluation, and consideration for therapy
for latent TB infection once active TB is ruled out.
Inmates known to have HIV infection should have
a chest radiograph as part of the initial screening,
regardless of their TST status.
To prevent transmission in some large jails, TB
control officials should consider using on-site
chest radiography in addition to skin testing to
screen all inmates for TB disease at entry into the
facility3.  Such screening is particularly important
for large jails where a combination of risk factors
(i.e., an incarcerated population with a very high
incidence of TB infection and disease, a high
prevalence of HIV infection and drug injection,
and a rapid turnover of inmates that make TST-
based screening inefficient) are present. Jail offi-
cials should consult the local TB control officer for
assistance in assessing the need and cost-effec-
tiveness of such screening.
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3.6% of all active M. tuberculosis
cases (TB) reported in the United
States were residents of correctional
facilities - a TB case rate 50 times
that of non-incarcerated individuals.
Continued on page 2
Follow-up Screening
Long-term inmates who have a negative skin
test reaction at intake should be skin tested
annually to detect skin test conversions.
Persons with a documented positive TST
result who have not previously received a
course of therapy for MTB infection and who
do not qualify for MTB prophylaxis  should be
screened each year for symptoms of TB dis-
ease (see qualifications below). Annual chest
radiographs are not necessary for the routine
follow-up of infected persons, providing a
qualified health provider interviews the patient
for symptoms of TB disease.
Diagnosis of Latent
Mycobacterium Tuberculosis
Infection
A positive skin test reaction in a person with-
out symptoms or signs suggestive of TB dis-
ease is considered indicative of latent MTB
infection. Whenever latent TB infection  is sus-
pected, an evaluation to rule out active TB and
assess the need for treatment of latent TB
infection should be conducted. This evaluation
consists of a medical history, physical exami-
nation, chest radiography, and, when indicat-
ed, bacteriologic studies. HIV testing is also
recommended. Any inmate who has symp-
toms suggestive of TB should be immediately
placed in a TB isolation room and promptly
evaluated for TB disease. Inmates should not
be returned to the general prison housing,
until infectious TB disease has been ruled out
by qualified medical personnel (See Isolation
Guidelines, HEPP News, March 1999).
Treatment for MTB Infection
The new guidelines simplify treatment by set-
ting the same duration of dosing regardless of
whether patients are co-infected with HIV, by
increasing the options for using intermittent
(i.e., twice weekly) regimens, and by recom-
mending the use of Rifampin-based short-
duration (i.e., 2-4 months) drug regimens (7).
Implementation of the new MTB infection
management recommendations may lessen
some of the continuing problems with adher-
ence to MTB infection  treatment in correction-
al settings. The major changes and additions,
some important background information, and
the potential applicability of the new guidelines
for correctional facility-settings are summa-
rized here.
Treatment Options (See Table 1)
1.Isoniazid for treatment of MTB infection
For all persons deemed to be candidates for
MTB infection  therapy, regardless of age, and
HIV serostatus, the preferred regimen is INH
daily for at least 9 months. ACET based this
decision on: (1) a review of the findings from
prospective, randomized clinical trials con-
ducted in HIV-negative persons that show that
12 months of INH treatment is more effective
than 6 months for the prevention of active TB;
(2) the results of subanalysis of some of these
trials that showed that maximal beneficial
effect of INH was mostly associated with ther-
apy that lasted for at least 9 months, and min-
imal additional benefit was observed for clini-
cal trial participants who had longer (i.e., 12
months) therapy duration; and (3) HIV status
is not a significant factor in the effectiveness of
TB prophylactic regimens (8-13). Thus, when-
ever possible, correctional facilities with long-
term stays should opt for using a 9-12 month
INH regimen for inmates who are deemed eli-
gible for treatment of MTB infection. This treat-
ment may be administered daily or twice
weekly under directly observed therapy
(DOT).
2. Rifampin and Pyrazinamide for treatment of
MTB infection
The 2-month daily regimen of rifampin and
pyrazinamide (PZA) is recommended based
on a prospective randomized trial of treatment
of MTB infection in HIV-infected persons that
showed the 2-month regimen to be similar in
safety and efficacy to a 12-month regimen of
INH. A similar large-scale clinical trial has not
been conducted in HIV negative persons;
however, the antituberculosis activity of
rifampin and PZA is not expected to differ for
those with HIV infection and those without HIV
infection. Some experts recommend that the
2-month regimen of daily rifampin and PZA
also be given by DOT, which can consist of
five observed and two self-administered doses
each week.
3. Treatment of INH-Resistant TB Infection
Some alternative options for therapy for MTB
infection are recommended for use in special
situations. For example, for contacts of
patients with Isoniazid-resistant, rifampin-sus-
ceptible TB, the recommended regimen is
Rifampin and Pyrazinamide given daily for 2
months; however, for patients with intolerance
to Pyrazinamide, Rifampin given daily for 4
months is recommended. A 4-month Rifampin
regimen is recommended based on the effica-
cy of a similar regimen in both a prospective
randomized trial of tuberculin-positive persons
with silicosis and non-randomized trial in per-
sons exposed to persons with Isoniazid-resis-
tant TB.
4. Treatment of MTB Infection in those receiv-
ing antiretroviral therapy
Complex pharmacologic interactions occur
when rifamycins (Rifampin & Rifabutin) are co-
administered with some antiretroviral agents,
notably protease inhibitors and non-nucleo-
side reverse transcriptase inhibitors. These
drug-drug interactions may result in either an
increase or decrease of the blood levels of
both rifamycins and antiretrovirals, leading to
adverse effects such as a decrease in anti-
retroviral activity or drug toxicities. Thus, ther-
apy for active TB or MTB infection with
rifamycins in HIV-infected persons should
always be done in consultation with a physi-
cian experienced in the care of patients with
TB and HIV co-infection. Except for Efavirenz,
Rifampin use is to be avoided with PIs and
NNRTIs (see HEPPigram on page 4).
Clinical and Laboratory
Monitoring During Therapy for
MTB Infection
Before the start of treatment for MTB infection,
all inmates should receive a clinical evalua-
tion. They should also receive follow-up eval-
uations for questioning about side effects and
a brief physical assessment to check for signs
of hepatitis at least monthly (if receiving
Isoniazid alone or Rifampin alone) and at 2, 4
and 8 weeks (if receiving Rifampin and
Pyrazinamide). Inmates should be educated
about the side effects associated with treat-
ment of MTB infection and at each visit
reminded of the need to stop treatment and
promptly report to medical personnel if signs
and symptoms of hepatoxicity appear (e.g.,
anorexia, abdominal pain, nausea, vomiting,
change in color of urine and feces, jaundice). 
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Screening of TB... 
(continued from page 1)
Table 1. TB Medication Daily and Twice-Weekly Dosing
TB Medication Daily Dose Twice-Weekly Dose
(DOTS recommended) (mg/kg body weight)
Isoniazid 5 (4-6) up to 300mg 15 (13-17)
Rifampin 10 (8-12) up to 600mg 10 (8-12)
Pyrazinamide 25 (20-30) up to 2.0g 50 (40-60)
Streptomycin 15 (12-18)  up to 1.0g 15 (12-18)
Ethambutol 15 (15-20)  45 (40-50)
Adapted from the World Heath Organizations publication: Treatment of Tuberculosis: Guidelines for National
Programs. Second ed. 1997.
Continued on page 4
Correctional facility inmates who have a posi-
tive skin test and no symptoms or signs of
active TB who are candidates for therapy
include:
TST>5mm
l Persons known to have or suspected of hav-
ing HIV infection, including persons who inject
drugs and whose HIV status is unknown 
l Close contact of a person with infectious TB 
l Persons who have chest radiograph find-
ings suggestive of previous TB and who have
received inadequate or no treatment 
TST>10mm
l Persons who inject drugs and are known to
be HIV negative 
l Persons with certain medical conditions
(diabetes mellitus, silicosis, low body weight,
etc.) that might increase risk of TB disease 
Converter
l Persons whose TST reaction converted
from negative to positive within the past 2
years (=10mm increase if younger than 35;
=15mm increase if older than 35.) (6)
Dear Colleagues,
The Ides of March are upon us, and just as in Julius Caesar’s time, tuberculosis remains a
worldwide scourge. Dramatic decreases in MTB case rates and deaths in the USA this past
century belie the worldwide situation.  Globally, one person is infected with MTB every sec-
ond, there are three million MTB related deaths every year, and an estimated one-third of
the population is infected with MTB. Rising rates of active MTB among those co-infected
with HIV, increasing reports of multiple drug-resistant MTB, and logistical problems associ-
ated with the provision of expensive long-term, multi-drug therapy to those least able to
afford it, contributed to the World Health Organization’s decision to designate MTB as a
global emergency in 1995.
Our incarcerated patients often do not readily access healthcare in the free world. We in cor-
rections, therefore, have a unique opportunity and responsibility to make a major public
health impact in the area of MTB prevention and treatment. Certainly the Advisory Council
for the Elimination of Tuberculosis’ goal of worldwide eradication of MTB by 2010 will not be
met without the coordinated efforts of all of us working in correctional healthcare!
This month’s HEPP News features an article by Elsa Villarino, MD on the Screening and
Prevention of TB in Correctional Facilities. Staff testing and strategies for the management
of the less cooperative inmate/patient such as those with co-morbid mental illness will be
addressed in a future issue. Also this month is a table detailing significant pharmacokinetic
interactions between ART and rifamycins; a Heppigram outlining management of MTB in the
HIV-infected patient, reports from the 7th Conference on Retroviruses and Opportunistic
Infections, and a patient scenario involving an individual co-infected with HIV and MTB. After
reviewing this issue, readers should be able to identify candidates for TB screening and
treatment, know which TB and HIV medications to recommend and how to manage TB
patients co-infected with HIV, and be familiar with the latest updates concerning TB from the
7th Conference on Retroviruses and Opportunistic Infections.
As always, we encourage your comments and suggestions for future HEPP news topics.
Sincerely,
Joseph Bick, M.D.
Letter from the Editor
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4HEPPigram
Patient has active MTB 
and HIV infection, 
not on antiretroviral therapy.
Patient is receiving ART
for HIV and is diagnosed
with active MTB
CD4 > 350,
HIV VL < 30,000
Wants to stop ART
Discontinue
ART, treat
MTB with
Rifampin
based 
regimen
On-going ART indicated
and patient wants to
continue ART
Use Rifabutin based MTB treatment 
regimen, dose adjusting as needed*
or
Use Streptomycin based MTB treatment 
regimen without a Rifamycin
or
Use Combivir (AZT/3TC) and Efavirenz (EFV)
or
Use regimen based on EFV
CD4 < 350 and/or HIV
VL > 30,000 and patient
wants to begin ART
Use Rifampin based
MTB treatment 
regimen, re-evaluate for
ART within 3 months
Use Rifabutin based
MTB treatment regimen
and initiate ART*
Recommended Management Strategies for Patients With Both HIV and Active Tuberculosis
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Baseline laboratory testing is not routinely indi-
cated for all persons at the start of treatment
for MTB infection, however, based on the rela-
tively high prevalence of chronic liver disease
(e.g., Hepatitis B or C, alcoholic hepatitis, or
cirrhosis) among the inmate population, base-
line hepatic measurements of serum AST
(SGOT) or ALT (SGPT) and bilirubin should
probably be considered for all persons in this
setting. Active hepatitis and end-stage liver
disease are relative contraindications to the
use of Isoniazid or Pyrazinamide for treatment
of MTB infection.
Routine laboratory monitoring during treat-
ment of MTB infection is indicated for persons
whose baseline liver function tests are abnor-
mal (>3 times upper level of normal), women
who are pregnant, and other persons with a
risk of hepatic disease. Laboratory testing may
also be indicated for the evaluation of possible
adverse effects that occur during the course of
treatment (e.g., liver function studies for
patients with symptoms compatible with hepa-
toxicity or a uric acid measurement to evaluate
complaints of joint pain). Persons with HIV
infection are often treated with multiple drugs
in addition to antituberculosis drugs. During
the course of treatment for MTB infection all
other medications that a person is taking
should be reviewed and assessed for potential
drug interaction with TB medications. Efforts to
manage these potential problems related to
drug interactions require the coordinated
efforts of clinicians responsible for HIV and TB
care (See HEPPigram above).
Conclusion
Control of TB is an essential element in cor-
rectional health care. All correctional facilities,
even those in which few cases of TB are
expected, should have a written plan for the
screening and prevention of tuberculosis.
State TB officials are available for consultation
on the development of this plan. The strategic
application of these interventions, however,
should be based on the size and type of the
facility and the length of stay of the facility’s
inmates. All TB control personnel and clini-
cians who treat inmates or staff should be
familiar with the special problems that correc-
tional facilities may face arriving at a diagnosis
of TB disease or infection. Upon release from
correctional facilities, patients should be ref-
ered to local health departments in order to
keep the disease under control.  
When adherence to MTB infection treatment
regimens is identified as a problem following
the release of the inmates from the correction-
al facilities, TB control personnel from these
institutions, in collaboration with staff from TB
control programs at the local level, should
seek and develop well-defined procedures for
discharge planning, interagency collabora-
tions, and incentives to return for follow-up
appointments. The use of new ultra-short
course of therapy that may be completed
before release may also significantly benefit
the control of correctional facility-related TB.
Screening of TB... 
(continued from page 2)
Footnotes
1The CDC’s National Center for HIV, STD and TB Prevention website (http://www.cdc.gov/nchstp/tb) has the most updated guidelines on TB prevention and treat-
ment, as well as very useful algorithms on TB management. Local TB control officials for each state are also listed at this site.
2Abt Associates is currrently working with CDC on a study of the extent of adherence to CDC’s guidelines for TB control in a group of large jail systems serving
cities with higher than average TB incidence. Later this spring, Abt Associates will be sending a mail survey to these jail systems and the public health depart-
ments in these jurisdictions. Following the mail survey they will be conducting site visits to about 20 jurisdictions. CDC will use the study results to review the
guidelines and consider strategies for enhancing TB control in jails. Jail systems and health departments that are contacted regarding this study are urged to par-
ticipate. For further information, contact  Dr. Mark Lobato, the CDC Project Officer (404-639-8131) or Dr. Ted Hammett, the Abt Associates Project Director (617-
349-2734) 
3Correctional clinicians might find it useful to employ the mini-chest x-ray cassette-type   machines with rolls of 1,000 100x100mm exposures.  These avoid
excessive radiation exposure to frequent visitors to the jail, save space for the storing of films, and are less expensive than full size films.
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Expert Response: Dr. Joseph Bick, M.D.
For those of us practicing in congregate living environments (CLE)
such as jails and prisons, JS’s diagnosis must be tuberculosis (TB)
until proven to be otherwise. Clearly TB is not the most common
cause of pneumonia in those who are HIV infected, but because of
the devastating public health consequences of a missed or delayed
diagnosis, it must be ruled out. An aggressive approach is all the
more important in those systems that cluster immunodeficient
inmates. In designated HIV CLEs, progression to active TB can
occur within four to six weeks after infection and quickly result in an
epidemic. 
Faced with JS’s presentation, then, the decision must be to place
the patient in a negative pressure respiratory isolation room and
treat as a TB suspect case. This entails initiating empirical four drug
antitubercular therapy (unless major contraindications exist) induc-
ing three sputums for AFB stain and culture, and reporting the
patient to the public health department as a TB suspect case. 
S. pneumonia, H. influenza, and other bacteria remain the most
common causes of pneumonia in those who are HIV infected.
Notably, over 80% of S. pneumonia clinical isolates are contained in
the current vaccine and are therefore potentially preventable. If the
patient’s CD4 count is <200, pneumocystis becomes a common
cause of pneumonia. Although there is considerable overlap in the
presentation of pneumonia due to various organisms, there are
some clues to help with the diagnosis. If the PaO2 is <75, the LDH
>400, the infiltrates have an interstitial pattern, and the patient has
dyspnea on exertion the diagnosis is more likely to be PCP than TB.
If weight loss is a prominent feature, the diagnosis is more likely to
be TB. However, none of the features is specific enough to enable
one to eliminate the possibility of TB.
The presentation of TB can vary depending upon the immune sta-
tus of the patient. In those with CD4 counts >400, TB is usually a
reactivation disease and classically presents with upper lobe dis-
ease with or without cavitation. In this setting, extrapulmonary dis-
ease is uncommon. In those with lower CD4 counts, 30-50% of
cases are primary progressive (active disease develops shortly
after infection) rather than reactivation. 25-35% of these patients will
have extrapulmonary disease, often in the lymph nodes or bone
marrow. Blood cultures are positive 25-50% of the time. The most
common chest x-ray abnormality is mediastinal or hilar adenopathy.
A diffuse reticulonodular pattern is common. Induced sputum
smears are positive in 40-50% of cases of pulmonary TB.
Specimens obtained by bronchioalveolar lavage stain positive 50-
60% of the time, and cultures are positive in 80-90% of cases.
If a cavity is present on chest x-ray, tuberculosis is the most likely
cause. Other organisms that commonly cause cavitary lesions
include cryptococcus, coccidioidomycoses, and histoplasmosis.
Cryptococcus can present with a reticulonodular pattern, or nodules
that may cavitate. For those who have traveled to the southwest,
coccidioidomycoses often presents with a reticulonodular pattern
and can cause thin walled cavities. For those who have been along
the Mississippi valley or in Central/South America, histoplasmosis
can present with one to two millimeter nodules that can cavitate.
Less common causes of cavities include staphylococcus,
pseudomonas, rhodococcus, blastomycoses, and non-tuberculous
mycobacteria.  
Silver and AFB stains of sputum were negative, and a sputum gram
stain showed gram-positive rods. Chest x-ray showed multiple 1-
3mm radiopaque lesions on both lung fields. Bronchial lavage was
negative for fungus, PCP, AFB stain and malignancy. Previous
chest x-ray on June 1998 was normal. Patient was initially treated
empirically with Bactrim 5 mg/kg I.V. Q 6 h.  A DNA probe was pos-
itive for MTB complex. A lung wedge biopsy was negative for malig-
nancy, fungus, and for AFB. Patient was placed in respiratory isola-
tion and treated with INH, Rifabutin, Ethambutol, and Pyrazinamide
in addition to the above antiretrovirals, with a diagnosis of miliary
Tuberculosis.
In JS’s case, a gene probe from one of his respiratory specimens
was positive for TB.  We should all ensure that the labs which
process our mycobacterial specimens do in fact utilize a bactec sys-
tem and gene probe technology so that positive diagnoses can be
made promptly.  JS was placed on antitubercular therapy, and, I
assume, was released from isolation after 1) he was clinically
improved, 2) he had received two weeks of directly observed anti-
tubercular therapy (DOT), and 3) he had three consecutive negative
sputum smears for AFB. His TB regimen was selected taking into
account potential pharmacokinetic interactions with his ART. 
The patient did well until February 1999 when he developed mild
confusion, ataxia and memory loss.
The differential diagnosis at that time was broad, and included drug
intoxication, hepatic encephalopathy from his known Hepatitis C,
electrolyte abnormalities, endocarditis from his IVDU with CNS
Ask the Expert
Case: JS is a 44 year-old male who has been incarcerated multiple times since the age of 22. He has a history of IVDU and crack cocaine
use, and was diagnosed with HIV in 1988 and HCV in 1996.  He refused antiretrovirals until May 1998, when he enrolled in ACTG 388 (AZT,
3TC, and efavirenz).  At therapy initiation, CD4 was 22 and CD4% 1.8. The patient did well until July 1998 when AZT was discontinued because
of anemia and replaced with d4T.  Four weeks later the patient became febrile (105.1 F), tachycardic (130), tachypnic (28), but blood pressure
was normal (110/70). The patient also complained of non-productive cough for two months and weight loss.  At this time the CD4 was 95 and
CD4% 7.3, HIV-1 RNA 130,000 copies/mL.
California Department of Corrections, California Medical Facility, Vacaville
In designated HIV CLEs, progression to active
TB can occur within four to six weeks after
infection and quickly result in an epidemic.
We should all ensure that the labs 
which process our mycobacterial specimens 
do in fact utilize a bactec system 
and gene probe technology so that 
positive diagnoses can be made promptly.
Continued on page 6
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Abstract 246
This Swiss cohort study evaluated the safety of stopping or with-
holding primary prophylaxis for disseminated Mycobacterium avium
(dMAC) in those whose CD4 count had risen while on ART from <50
to >100. In 253 patients followed for 364 patient-years, no cases of
dMAC developed.
Abstract 247
CPCRA study 048 evaluated the benefit of weekly dMAC prophy-
laxis with azithromycin vs. placebo in those with CD4 previously
<50 but now >100 while on ART. 520 patients were followed for a
median of 12 months. There were no differences in the percent of
individuals who developed dMAC, progression of HIV disease, bac-
terial pneumonia, or death in the treatment vs. placebo groups.
Abstract 255
This Italian observational study evaluated the risk of HIV infected
patients developing active MTB based upon their receipt of ART.
Those on no ART had a markedly increased risk as compared to
those on ART. Those on at least three agents had one half the risk
of those on two agents.
Abstract 258
This abstract from Florida described paradoxical reactions in HIV-
infected patients under treatment for MTB who were started on ART.
Six patients developed new or worsening CNS lesions after the ini-
tiation of ART that did not respond to empiric anti-toxoplasma ther-
apy. Symptoms included headache, weakness, mental status
changes, new seizures nausea and emesis. Symptoms began a
median of 18 days (10-59) after initiation of ART. All patients
required corticosteroids. (See this month’s expert case for a dis-
cussion of immune reconsitution syndrome).
Abstract 243
In ACTG 88, PCP prophylaxis was withdrawn from two groups: 144
patients with a past history of CD4<100 but now >200 while on ART
and 125 patients with a past history of PCP who now had >200 CD4
while on ART.  During a follow-up of 46 weeks, no patients in either
group developed PCP. 
Abstract 230
In this Spanish study, 302 patients with HIV, a past CD4<100, and
positive toxoplasma serology currently on ART with CD4 >200 and
VL<5000 for at least three months were randomized to either con-
tinue or stop toxoplasma prophylaxis. After a 10-month follow-up,
there were no cases of toxoplasma encephalitis or death in either
group.
Abstract 231
This Roche study evaluated an oral ganciclovir prodrug valganci-
clovir vs. intravenous ganciclovir in the induction and maintenance
therapy of 160 patients with newly diagnosed CMV retinitis. Both
regimens yielded similar results in terms of response to therapy and
time to progression.
Abstract 250
This intriguing small study (six patients) from UCSF looked at dis-
continuing cryptococcal meningitis maintenance therapy in HIV
infected patients who were asymptomatic for at least four months,
had received 12 months of fluconazole, had CD4 >150, and were
receiving ART for at least four months. During eight weeks of follow-
up, none of the patients became symptomatic or had increases in
their serum or CSF cryptococcal antigen titres.
Conference News
Tuberculosis and Opportunistic Infection Highlights from the 7th Conference on Retroviruses and Opportunistic Infections
The 7th Conference on Retroviruses and Opportunistic Infections was held January 30 through February 2, 2000, in San Francisco, CA.
The following is a synopsis of the abstracts that were relevant to tuberculosis. Next month’s issue of HEPP News will review the abstracts
related to HIV resistance from the Retrovirus conference.
emboli, PML, CNS infectious etiologies such as neurosyphilis, cryp-
tococcus, toxoplasmosis, and a variety of viral encephalitides. If the
results of serum glucose, electrolytes, ammonia and CBC did not
readily explain his condition, the next step would be to proceed to
a brain scan followed by a lumbar puncture.
A CT scan of the brain showed multiple supratentorial hyperdense
lesions. MRI of the brain showed multiple enhancing lesions in the
central hemispheres.
In JS’s case, a brain scan revealed multiple enhancing lesions,
which in the setting of HIV disease is most likely due to toxoplas-
mosis or malignancy (i.e. lymphoma). I will assume that JS had
been receiving all of his TB therapy by DOT, his isolate was found
to be pansusceptible and had adhered perfectly.  If that were not the
case, one would also need to worry about CNS tuberculomas as
the etiology of his current presentation. 
In HIV infected patients with CD4 <200, multiple ring enhancing
lesions on brain scan, and a positive serum toxoplasma IgG, the
usual practice is to initiate empirical anti-toxoplasma therapy.  If
there is a lack of response at two weeks, one should consider brain
biopsy to rule out other etiologies.  In those with less classic brain
scan presentations and/or negative toxoplasma IgG, one might con-
sider earlier biopsy.  In JS’s case, his ART had resulted in a dra-
matic improvement in his immunologic status with an increase in his
CD4 to 580.  
On April 1999 a brain biopsy showed tuberculosis encephalitis.
Since the widespread use of highly active ART, numerous syn-
dromes have been described which have been attributed to the
host’s improved ability to mount an effective immune response to
various pathogens. Even in the setting of effective therapy against
various opportunistic infections, ART induced immunologic recov-
ery has led to apparent clinical deterioration. Mycobacterium avium
has worsened with mesenteric and thoracic adenopathy, CMV
retinitis has presented or worsened, chronic Hepatitis B has flared,
and TB has worsened with the recurrence of fevers and lym-
phadenopathy.
Certainly, clinicians must always be on the lookout for a new oppor-
tunistic infection (OI) or non-adherence to OI therapy as the cause
of such syndromes.  However, in the setting of newly initiated ART
with virologic and CD4 responses, one must consider the possibili-
ty that the patient is experiencing an IRS and not treatment failure.
Ask the Expert... 
(continued from page 5)
Clinical Updates in Correctional
Health Care: A Multi Disciplinary
Educational Conference
March 19-21, 2000
New Orleans, Louisiana
Call: NCCHC 773.880.1460
Fax: 773.880.2424
Visit: www.ncchc.org
HIV Pathogenesis, Antiretrovirals,
and Other Selected Issues in HIV
Disease Management
March 22, New York, NY
April 19, Chicago, IL
Aptil 25, San Francisco, CA
May date TBA, Dallas, TX
and Washington, DC
Call: 415.56.6725
Fax: 415.56.6740
E-mail: cme@iasusa.org
Visit: www.iasusa.org
Sponsor: International AIDS Society  
National Conference on
Pharmaceutical Care to 
Underserved Populations
April 3-4, 2000
Chapel Hill, NC
Call: 919.966.8138
Email: steve_moore@unc.edu
Sponsors: School of Pharmacy and
Cecil Sheps Center for Health
Services Research, UNC at Chapel
Hill, HRSA, NC Assn of Pharmacists
CME available
10th International Symposium on
Viral Hepatitis and Liver Disease
April 9-13, 2000
Marriott Marquis, Atlanta Hilton
Towers & Hyatt Regency Hotel
Atlanta, GA
Call: Harold Margolis 404.639.2339
Visit: www.HEP2000.com
HIV Prevention with 
Incarcerated Persons
A Public Health Training Network
Satellite Broadcast
April 27, 2000  1:00-3:00 PM EST
Call: 800.458.5231 or 
TTY 800.243.7012
Visit: www.cdcnpin.org/broadcast
Sponsor: CDC’s National 
Prevention Information Network
10th Annual Clinical Care Options
for HIV Symposium
May 4-5, 2000  
Scottsdale, AZ
Call: 888.391.3996
Fax: 508.528.7880
Email: registration@mail.medscape.com
Visit: http://hiv.medscape.com/
symposium2000
Sponsors: N.W. Univ. Medical School
Comprehensive AIDS Center
Drug Use, HIV and Hepatitis:
Bringing it All Together 
May 7-10, 2000
Baltimore, MD 
Call: 877.565.3693
Fax: 301.565.3710 
Visit: www.chhatt.net/conference.html
Sponsors: CSAT of  SAMHSA, NIDA
of NIH, and the CDC.
Save the 
Dates
News Flashes
HAART May Allow Discontinuation of CMV
Prophylaxis
Anti-CMV maintenance therapy likely can be
safely stopped in some patients on HAART with
Cytomegalovirus (CMV) retinitis if CD4+ cell
counts are stable or increasing and have been
higher than 0.10x109/L for at least 3 months.
Immune recovery in patients receiving HAART
has been effective in controlling opportunistic
infections, but it may also result in intraocular
inflammation, which can have adverse effects on
the eye. Scott Whitcup, MD, discusses the
prevalence of uveitis among 28 patients who
have demonstrated a similar clinical course in
the February 2 issue of JAMA, (Whitcup, C.
JAMA 2/2/2000;283: 653-257.)
FDA Approves Once Daily Dosing for
Didanosine
Once-daily dosing is approved for didanosine
(200mg tablets), meaning two 200mg tablets
once a day. This new dosing exposes patients to
50% less antacid buffer per daily does. The
200mg tablet should not be used for BID dosing,
since two tablets are required for adequate
buffering. For more information, go to
http://www.fda.gov/cder/approval/
GAO Releases Study on Women in Prison
The nation’s female inmate population in state
and federal prisons in the 1990s doubled, grow-
ing faster than the male population, according to
a study released January 31 by the General
Accounting Office. The study, commissioned by
Del. Eleanor Holmes Norton (D-D.C.), also found
that the majority of women in prison are incarcer-
ated for nonviolent crimes, are mothers and are
incarcerated at great distances from their chil-
dren, and that women in prison are more likely to
suffer from HIV infection and mental illness than
men are. The GAO looked specifically at the fed-
eral Bureau of Prisons, the California
Department of Corrections and the Texas
Department of Criminal Justice-the nation’s three
largest prison systems. Female incarceration for
violent crimes in state prisons has decreased
from 49 percent in 1979 to 28 percent in 1997,
and for property crimes from 37 percent to 27
percent in that period. These findings suggest
that women are being incarcerated for drug
crimes committed often to feed drug habits and
for less serious property crimes than men. The
full report is available at
http://www.gao.gov/audit.htm.
FDA Public Health Advisory: St. John’s Wort,
Indinavir and other drugs
The Food and Drug Administration (FDA) issued
a Public Health Advisory February 10, 2000
alerting health providers to the risk of drug inter-
actions with St. John’s Wort and Indinavir and
other drugs. Results from a study conducted by
the National Institutes of Health showed a signifi-
cant drug interaction between St. John’s Wort
(hypericum perforatum), an herbal product sold
as a dietary supplement, and Indinavir, a pro-
tease inhibitor used to treat HIV infection.  In this
study, concomitant administration of St. John’s
Wort and Indinavir substantially decreased indi-
navir plasma concentrations, potentially due to
induction of the cytochrome P450 metabolic
pathway. Consequently, concomitant use of St.
John’s Wort with PIs or NNRTIs is not recom-
mended because this may result in suboptimal
antiretroviral drug concentrations, leading to loss
of virologic response and development of resis-
tance or class cross-resistance. For more infor-
mation, refer to Piscitelli et al. Lancet. 2/12/2000.
The health advisory is available at
http://hivatis.org/stjohn.html?list
World Tuberculosis Day 2000 Approaches
World TB Day on March 24, 2000 marks a key
date for mobilizing political will and encouraging
the involvement of civil society in the global
efforts to stop TB. The theme, Forging new
Partnerships to Stop TB, is a call to reach out
beyond the TB community and to mobilize new
TB constituencies such as international agencies
and organizations, women’s groups, human
rights groups, HIV/AIDS groups, and others to
join the global movement to stop TB. For more
information go to the WHO TB home page:
http://www.who.int/gtb/index.htm
W Variant Outbreak of TB Identified with
Population-Based Molecular Epidemiology
Variants of the New York City Strain W of M
tuberculosis (TB) were identified in New Jersey
using a more sensitive type of epidemiologic
study. The population-based cross-sectional
study revealed that the TB outbreak in New
Jersey included two types of the multi-drug resis-
tant strain W. Groups A (43 patients) shared a
unique banding motif not shared by other W fam-
ily isolates, and group B (25 patients) included
strains that did not have that motif. Patients in
group A were more likely to be US-born (91%),
black (76%), HIV-infected (40%) and residents of
urban northeast New Jersey counties. According
to Bifani et al, the findings are useful in showing
epidemiological outbreak patterns, and they
helped to identify a previously unknown outbreak
in a specific area. (Bifani PJ, Mathema B, Liu Z,
et al. JAMA. 12/29/99; 282(24): 2321). 
April HEPP News
Main Article: Dr. Rick Altice will discuss the lat-
est news about HIV drug-resistance testing.
HIV 101: Review how to read a gel diagram for
common gene mutations.
Ask the Expert: Discuss a deep salvage case.
Spotlight: Highlight the Florida DOC’s genotyping
plan.
Coming Next Month . . .
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1 Pharmacokinetic Interactions Between
Antiretroviral Agents and Rifamycins
ANTIRETROVIRAL
AGENT
NRTIs*
Nevirapine (NVP)
Delavirdine (DLV)
Efavirenz (EFV)
Ritonavir (RTV)
Saquinivir (SQV)
Nelfinavir (NFV)
Indinavir (IDV)
Amprenavir (AMP)
*Nucleoside reverse transciptase inhibitors.
Modified from Guidelines for the Use of Antiretroviral Agents in HIV Infected Adults and Adolescents, MMWR October 30, 1998 / 47(RR20); 1-51. Available at
www.cdc.gov/mmwr
RIFAMPIN
No significant interaction
NVP decreased 37%. Co-administration 
not recommended.
DLV decreased 96%. Co-administration 
contraindicated
EFV decreased 25%. No dose change required.
RTV decreased 35%. No data available on dose
change.
SQV decreased 84%. Co-administration 
contraindicated.
NFV decreased 82%. Co-administration 
contraindicated.
IDV decreased 89%. Co-administration 
contraindicated.
AMO decreased 82%. Avoid co-administration.
RIFABUTIN
No significant interaction
No data
DLV decreased 80%. Rifabutin increased 100%. 
Co-administration not recommended.
EFV not changed. Rifabutin decreased 35%. 
Increase Rifabutin to 450mg QD.
Rifabutin increased 400%. Decrease Rifabutin 
to 150mg QOD.
SQV decreased 40%. Co-administration 
not recommended.
NFV decreased 32%. Rifabutin increased 200%.
Decrease Rifabutin to 150mg QD and increase IDV 
to 1000mg TID.
IDV decreased 32%. Rifabutin increased 200%.
Decrease Rifabutin to 150mg QD and increase IDV 
to 1000mg TID.
AMP decreased 15%. Rifabutin increased 193%. 
No change in AMP. Decrease Rifabutin to 150mg QD.
Updated Guidelines available on the Web
The updated Guidelines for the Use of Antiretroviral Agents in
HIV-Infected Adults and Adolescents is now available on the
HIV/AIDS Treatment Information Service (ATIS) at
www.hivatis.org in both portable document format (PDF) and web
format.  Single copies can be ordered at 800.448.0440 or e-mail
atis@hivatis.org.
TB Websites:
Morbidity and Mortality Weekly Report on Tuberculosis:
October 30, 1998 / 47(RR20);1-51
www.cdc.gov/mmwr
Francis J Curry National Tuberculosis Center
http://www.nationaltbcenter.edu
Post-Exposure Prophylaxis Network
http://epi-center.ucsf/edu/PEP/pepnet.html
NJ Medical School National TB Center
http://www.undnj.edu/ntbc
Brown University TB/HIV Research Lab
http://www.brown.edu/research/TB-HIV_Lab/
World Health Organization Tuberculosis Website
http://www.who.int/gtb/index.htm
CDC’s National Center for STD, HIV, and TB Prevention
http://www.cdc.gov/nchstp/od/nchstp.html
Related Websites:
Medscape HIV/AIDS
http://hiv.medscape.com
Johns Hopkins AIDS Service
http://www.hopkins-AIDS.edu
JAMA HIV/AIDS Information Center
http://www.ama-assn.org/special/hiv
International Association of Physicians in AIDS Care (IAPAC)
http://www.iapac.org
7th Conference on Retroviruses and Opportunistic Infections
http://www.retroconference.org/
Doctor’s Guide to the Internet: a straightforward guide to
internet medical resources
http://www.docguide.com
AEGIS-AIDS Education Global Information System
http://www.aegis.com
Telephone Numbers:
National Clinicians’ PEP Hotline:
888.448.4911
National TB Center at the NJ Medical School:
973.972.3270
TB Infoline
800.4TB.DOCS
National HIV Telephone Consultation Services:
800.933.3413
CDC National AIDS Hotline (24 hours):
800.342.AIDS
Resources
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Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians
Recognition Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of
the questions. A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through 
April  30, 2000. The estimated time for completion of this activity is one hour and there is no fee for participation.
1. Which of the following drugs is acceptable for co-administra-
tion with Rifampin?
a) Nelfinavir (NFV)
b) Delavirdine (DLV)
c) Saquinavir (SQV)
d) Efavirenz (EFV)
e) Indinavir (IDV)
2. Indicate which of the following sentences are true?
a) All inmates should be screened for TB signs or symptoms 
at intake.
b) Inmates known to have HIV infection should have a chest 
radiograph as part of the initial screening, regardless of their 
TST status  
c) Placement in a negative pressure respiratory isolation 
room is necessary for any inmate who presents with 
symptoms suggestive of TB.
d) All of the above
e) None of the above
3. A patient presents with active MTB and HIV infection who is
currently not on ART, and has a CD4 of >350 and viral load of
<30,000. How do you initiate treatment?
a) Use rifabutin-based MTB treatment regimen, and initiate 
ART (making appropriate dosage adjustments).
b) Use streptomycin-based MTB treatment regimen.
c) Use rifampin-based MTB treatment regimen, 
and re-evaluate for ART within 3 months.
d) Start either Combivir (AZT/3TC) and EFV or any 
EFV-based regimen.
4. Which of the following statements are true about differential
diagnosis of PCP and TB?
a) If the PaO2 is less than 75, the LDH is greater than 400, 
the infiltrates have an interstitial pattern, and the patient has 
dyspnea on exertion, the diagnosis is more likely to be TB 
than PCP.
b) If weight loss is a prominent feature, the diagnosis is 
definitively TB.
c) Pneumonia and TB present so similarly the only way to 
distinguish them is through chest radiograph.
d) a, b
e) None of the above features are specific enough to enable 
one to eliminate the possibility of TB.
5. Which condition(s) may contraindicate the use of Isoniazid or
Pyrazinamide?
a) HIV infection
b) Diabetes mellitus
c) Low body weight (10% or more below the ideal)
d) Active Hepatitis
e) End-Stage Liver Disease
6. Recent studies have suggested that:
a) It may be safe to discontinue MAC prophylaxis in those 
receiving ART with CD4 counts >100
b) Discontinuation of toxoplasma prophylaxis in those 
receiving ART whose CD4 counts have risen to >200 leads 
to an increased risk of toxoplasma encephalitis
c) It may be safe to discontinue PCP prophylaxis in those on
ART whose CD4 count  has risen to >100
d) The rate of completion of two months of pyrazinamide 
plus rifampin for MTB prevention is significantly less than 
that of nine to twelve months of daily isoniazid 
BROWN UNIVERSITY SCHOOL OF MEDICINE  OFFICE OF CONTINUING MEDICAL EDUCATION  BOX G-A2  PROVIDENCE, RI 02912
The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor 
continuing medical education activities for physicians.  
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, 
recommendations and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or 
speak for the Brown University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1   
HEPPigram 5  4  3  2  1   5  4  3  2  1   
HIV 101 5  4  3  2  1   5  4  3  2  1   
Updates 5  4  3  2  1   5  4  3  2  1   
Save the 5  4  3  2  1   5  4  3  2  1   
Dates
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
March 2000     Volume 3, Issue 3 visit HEPP News online at www.hivcorrections.org 9
